Tango Therapeutics (TNGX) announced that the first patient has been dosed in the TNG456 Phase 1/2 trial in patients with MTAP-deleted solid tumors, with a focus on glioblastoma. TNG456 is a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics: Promising Developments and Strategic Focus Justify Buy Rating
- Tango Therapeutics Extends Cash Runway Amid Clinical Progress
- Tango Therapeutics files $400M mixed securities shelf
- Tango Therapeutics sees cash runway into 1Q27
- Tango Therapeutics reports Q1 EPS (36c), consensus (35c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue